Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort

Simona Di Giambenedetto, Francesca Paola Fusco, Alessandro Grimaldi, Vanni Borghi, Filippo Lagi, Alessandra Latini, Gabriella D’Ettorre, Letizia Oreni, Paolo Fusco, Amedeo Capetti, Andrea Giacomelli, Giordano Madeddu, Gaetana Sterrantino, Cristina Mussini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Dolutegravir (DTG) is currently one of the most used Integrase inhibitors (INI) in antiretroviral therapies (ARV) in both naïve and experienced people living with HIV (PLWHIV). We analyzed a multicenter cohort of PLWHIV, both naïve and experienced, starting an ARV including DTG. We enrolled 3775 PLWHIV: 2763 (73.2%) were males, with a median age of 50 years. During 9890.7 PYFU, we observed 930 discontinuations (9.4 per 100 PYFU). Estimated probabilities of maintaining DTG at three and five years were 75.1% and 67.2%, respectively. Treatment-naïve pts showed a lower probability of maintaining DTG at three and five years compared to treatment-experienced PLWHIV (log-rank p < 0.001). At a multivariate analysis, a longer time of virological suppression (aHR 0.994, p < 0.001) and having experienced a previous virological failure (aHR 0.788, p = 0.016) resulted protective against DTG discontinuation. Most discontinuations (84.0%) happened within the first 12 months of DTG initiation, in particular, 92.2% of discontinuations due to neuropsychiatric toxicity were observed in the first year. Our data confirm the overall good tolerability of DTG in clinical practice, with a low rate of discontinuations. CNS toxicity resulted the main reason for DTG discontinuation, with most related interruptions happening in the first year from DTG introduction.
Lingua originaleEnglish
pagine (da-a)1-6
Numero di pagine6
RivistaViruses
Volume14
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • Dolutegravir
  • Toxicity
  • HIV
  • HAART

Fingerprint

Entra nei temi di ricerca di 'Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort'. Insieme formano una fingerprint unica.

Cita questo